QUOTE AND NEWS
FiercePharma  7 hrs ago  Comment 
Early on in the cancer drug pricing debates, doctors at Memorial Sloan Kettering Cancer Center made waves by rejecting a new Sanofi colon cancer drug as too expensive for its benefits. Now, the noted hospital has taken its cost-benefit analysis to...
FierceBiotech  Jun 18  Comment 
In this week's EuroBiotech Report, Neil Woodford's fund got deeper into Circassia, pulled out of Sanofi and criticized GlaxoSmithKline for performing "poorly operationally." Servier scooped up regional rights to Taiho Pharmaceutical's refractory...
FiercePharma  Jun 18  Comment 
It's no secret that Big Pharma isn't winning the popularity contest, as pricing pressures, safety issues and regulatory drama continue to take their toll on drugmakers' reputations. But some companies are faring better than other in the eyes of...
GenEng News  Jun 18  Comment 
Scientists at the University of California, San Diego School of Medicine (UCSD) reported the results of a proof-of-principle study with a small group of metastatic colorectal cancer patients to better predict how patients will respond to...
FierceBiotech  Jun 17  Comment 
Neil Woodford has pulled out of Sanofi and doubled down on Circassia, snapping up a 13.5% stake in the British allergy specialist. The deals were two of a string of stock sales and buys made by the fund manager as he shuffled his deck in recent...
FiercePharma  Jun 17  Comment 
After last week's expert panel meetings, the FDA may put some label limits on PCSK9 cholesterol drugs. But Sanofi, Regeneron and Amgen can take heart. 
newratings.com  Jun 15  Comment 
PARIS (dpa-AFX) - Genzyme, a Sanofi (SNYNF, SNY) company, announced that the first pediatric patient has begun treatment in a Phase 1/2 clinical trial focused on evaluating the investigational therapy olipudase alfa. Olipudase alfa is an enzyme...
FiercePharma  Jun 12  Comment 
Some industry watchers are wondering whether those large, expensive trials--which aren't long enough to establish long-term outcomes--were worth it.




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki